{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:55:47Z","timestamp":1790506547162,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaip.2019.05.053","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T23:35:37Z","timestamp":1560382537000},"page":"2689-2696.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma"],"prefix":"10.1016","volume":"7","author":[{"given":"Pasquale","family":"Comberiati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Malka-Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.05.053_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.05.053_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaip.2018.05.032","article-title":"Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma","volume":"7","author":"Ilmarinen","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaip.2017.05.015","article-title":"Severe asthma phenotypes\u2014how should they guide evaluation and treatment?","volume":"5","author":"Fitzpatrick","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib7","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaip.2017.04.038","article-title":"Biologic therapy and novel molecular targets of severe asthma","volume":"5","author":"Pepper","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.05.053_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"25","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2016.08.008","article-title":"Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma","volume":"139","author":"Yancey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaip.2017.04.031","article-title":"Severe asthma in children","volume":"5","author":"Ramratnam","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2010.11.015","article-title":"Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health\/National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"127","author":"Fitzpatrick","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jaci.2016.09.028","article-title":"Individualized therapy for persistent asthma in young children","volume":"138","author":"Fitzpatrick","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib17","series-title":"Pocket guide for asthma management and prevention","author":"Global Initiative for Asthma (GINA)","year":"2019"},{"key":"10.1016\/j.jaip.2019.05.053_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry, 1994 update","volume":"152","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib20","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM197505292922204","article-title":"Total eosinophil counts in the management of bronchial asthma","volume":"292","author":"Horn","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1067\/mai.2003.97","article-title":"Update on glucocorticoid action and resistance","volume":"111","author":"Leung","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1378\/chest.124.4.1318","article-title":"A\u00a0comparison of the clinical characteristics of children and adults with severe asthma","volume":"124","author":"Jenkins","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.05.053_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARPIII) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2016.11.029","article-title":"Changing paradigms in the treatment of severe asthma: the role of biologic therapies","volume":"5","author":"Katial","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","article-title":"Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study","volume":"55","author":"Albers","year":"2018","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.05.053_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","article-title":"Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma","volume":"11","author":"Ortega","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2019.05.053_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1378\/chest.111.4.852","article-title":"Airways remodeling is a distinctive feature of asthma and is related to severity of disease","volume":"111","author":"Chetta","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.05.053_bib30","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1164\/rccm.200209-1030OC","article-title":"Airway structural alterations selectively associated with severe asthma","volume":"167","author":"Benayoun","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib31","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.05.053_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00220413","article-title":"The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia","volume":"44","author":"Ortega","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.05.053_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaci.2016.09.002","article-title":"Current application of exhaled nitric oxide in clinical practice","volume":"138","author":"Spahn","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib34","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.05.053_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.05.053_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0091-6749(98)70165-4","article-title":"Patterns of steroid response in difficult-to-control asthma: clinical characteristics of steroid insensitive asthma","volume":"101","author":"Chan","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819305501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819305501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:02Z","timestamp":1761974522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819305501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2213219819305501"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.05.053","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.05.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}